Patents by Inventor Suning Chen

Suning Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYPEPTIDE BASED ON RECEPTOR-INTERACTING PROTEIN KINASE-3 METHYLATION MODIFICATION AND APPLICATION THEREOF IN CELL NECROPTOSIS-RELATED DISEASES
    Publication number: 20250000952
    Abstract: A polypeptide based on RIP3 methylation modification and application thereof in cell necroptosis-related diseases are provided, belonging to the technical field of biomedicine. The polypeptide for inhibiting intestinal inflammatory injury (TAT-mRIP3-SDMA) is formed by connecting cell-penetrating peptide TAT and methylated RIP3 polypeptide.
    Type: Application
    Filed: March 22, 2024
    Publication date: January 2, 2025
    Applicant: Air Force Medical University of the People's Liberation Army
    Inventors: Jian Zhang, Pan Zhao, Suning Chen
  • Use of tadalafil as protein arginine methyltransferase (PRMT5) inhibitor
    Patent number: 11369602
    Abstract: The present invention provides use of Tadalafil as a protein arginine methyltransferase 5 (PRMT5) inhibitor. The present invention finds out that Tadalafil is a PRMT5 inhibitor by virtually screening active compounds targeting PRMT5 based on crystal structure and information about active sites of PRMT5. The present invention not only confirms that Tadalafil can inhibit an enzymatic activity of PRMT5, but also confirms that Tadalafil alone can inhibit tumor growth in breast cancer and improve sensitivity to chemotherapy for breast cancer.
    Type: Grant
    Filed: August 2, 2020
    Date of Patent: June 28, 2022
    Assignee: Fourth Military Medical University of People's Liberation Army
    Inventors: Jian Zhang, Ying Wu, Rui Ling, Suning Chen, Lu Han, Wenxia Zhou
  • USE OF TADALAFIL AS PROTEIN ARGININE METHYLTRANSFERASE (PRMT5) INHIBITOR
    Publication number: 20210052581
    Abstract: The present invention provides use of Tadalafil as a protein arginine methyltransferase 5 (PRMT5) inhibitor. The present invention finds out that Tadalafil is a PRMT5 inhibitor by virtually screening active compounds targeting PRMT5 based on crystal structure and information about active sites of PRMT5. The present invention not only confirms that Tadalafil can inhibit an enzymatic activity of PRMT5, but also confirms that Tadalafil alone can inhibit tumor growth in breast cancer and improve sensitivity to chemotherapy for breast cancer.
    Type: Application
    Filed: August 2, 2020
    Publication date: February 25, 2021
    Inventors: Jian ZHANG, Ying Wu, Rui Ling, Suning Chen, Lu Han, Wenxia Zhou